Marc D. Succi

TL;DR: Ex vivo analysis of colon tissue samples from patients with ulcerative colitis demonstrated that IT-hydrogel microfibers adhered preferentially to mucosa from inflamed lesions compared with histologically normal sites, suggesting that this new gel-based delivery system could reach and directly treat areas of epithelial inflammation in humans.

TL;DR: The progression of the field toward technologies that are now beginning to capture aspects of this early vision of drug delivery are described, focusing on the two most prominent types of systems: the intravascular micro/nano drug carriers for delivery to the site of pathology and drug-loaded implantable devices that facilitate release with the predefined kinetics or in response to a specific cue.

TL;DR: In this paper, an inflammation-targeting hydrogel (IT-hydrogel) that acts as a drug delivery system to the inflamed colon was developed and shown to have preferential adhesion to inflamed epithelial surfaces.

TL;DR: In this paper, the authors report isolated unilateral axillary lymphadenopathy (i.e., no imaging findings outside of visible lymphadopathy), which is ipsilateral to recent (prior 6 weeks) vaccination, as benign with no further imaging indicated, with ultrasound if clinical concern persists 6 weeks after the final vaccination dose.